Archives
10058-F4 c-Myc-Max Dimerization Inhibitor
10058-F4 c-Myc-Max Dimerization Inhibitor
Executive Summary. 10058-F4 is described as a small molecule that inhibits c-Myc and Max heterodimerization, a protein interaction required for c-Myc-dependent transcription factor activity product information. The compound is listed as (5E)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one with molecular formula C12H11NOS2 and molecular weight 249.35 g/mol chemical specification. Reported downstream effects include reduced c-Myc DNA binding, suppression of PGC-1β transcriptional activation, cell-cycle arrest, and mitochondrial apoptosis reported mechanism. Acute myeloid leukemia cell-line studies involving HL-60, U937, and NB-4 reported myeloid differentiation and apoptosis-associated changes cell-model summary. Separate work found that APEX2 supports efficient TERT expression in human embryonic stem cells, but that study did not establish a connection to 10058-F4 Stern et al., 2024 preprint.
Biological Rationale
c-Myc is a transcription factor that regulates gene expression after forming a heterodimer with Max. The c-Myc/Max complex binds DNA at regulatory elements and activates transcriptional programs linked to proliferation, metabolism, and cell-state maintenance. Disrupting this interaction is therefore a strategy for studying c-Myc transcription factor inhibition without directly deleting the MYC gene.
10058-F4 is positioned as a c-Myc-Max dimerization inhibitor because it interferes with formation of the c-Myc/Max complex. The expected proximal consequence is reduced c-Myc association with DNA. The product dossier specifically identifies PGC-1β as a downstream transcriptional target whose activation is suppressed after treatment product mechanism summary.
This rationale connects molecular perturbation to measurable phenotypes. Researchers can measure c-Myc/Max-dependent DNA binding, PGC1B transcript abundance, c-Myc protein abundance, cell-cycle distribution, and apoptotic markers. Each readout addresses a different step and should not be treated as interchangeable evidence of dimerization blockade.
Mechanism of Action of 10058-F4 C-Myc-Max Dimerization Inhibitor
The proposed mechanism begins with inhibition of c-Myc/Max heterodimer formation. Reduced heterodimer formation limits c-Myc binding to DNA. Reduced DNA binding can suppress transcriptional activation of downstream targets, including PGC-1β, according to the product dossier reported activity.
Cellular responses reported after this perturbation include decreased c-Myc mRNA and protein levels. These changes are downstream observations and do not by themselves prove that 10058-F4 directly inhibits MYC transcription, translation, or protein stability. A mechanistic experiment should therefore pair c-Myc abundance measurements with a direct DNA-binding or dimerization assay.
In AML cell lines, the reported phenotype includes cell-cycle arrest, apoptosis, and myeloid differentiation. The apoptosis pathway is described as mitochondrial. Reported marker changes include lower Bcl-2, higher Bax, and cytochrome C release AML response summary. These markers support mitochondrial pathway involvement, but an apoptosis assay should include orthogonal measurements because altered Bcl-2 or Bax abundance alone does not establish execution of cell death.
The compound is supplied as a solid. It is reported to dissolve at concentrations of at least 24.9 mg/mL in DMSO and at least 2.64 mg/mL in ethanol. It is reported to be insoluble in water formulation information.
Evidence & Benchmarks
- 10058-F4 is reported to inhibit c-Myc/Max dimerization and reduce c-Myc-dependent DNA binding product evidence summary
- PGC-1β transcriptional activation is identified as a downstream process suppressed by the compound downstream-target summary
- Reported AML models include HL-60, U937, and NB-4 cell lines, where treatment was associated with cell-cycle arrest, apoptosis, and myeloid differentiation AML model summary
- The reported mitochondrial apoptosis pattern includes Bcl-2 downregulation, Bax upregulation, and cytochrome C release apoptosis-marker summary
- In SCID mice bearing human DU145 or PC-3 prostate cancer xenografts, intravenous administration at 20–30 mg/kg daily for two weeks produced reported tumor-control effects that varied by model in vivo benchmark
- The listed molecular weight is 249.35 g/mol, and the listed molecular formula is C12H11NOS2 chemical specification
These benchmarks support use in acute myeloid leukemia research, c-Myc pathway studies, apoptosis assays, and prostate cancer xenograft model design. They do not establish clinical efficacy, therapeutic dosing, or activity in every MYC-dependent tumor.
Applications, Limits & Misconceptions
10058-F4 can be used as a pharmacological perturbation tool for testing whether a cellular phenotype depends on c-Myc/Max-mediated transcription. In cell experiments, a strong design links treatment to a proximal molecular readout and a distal phenotype. For example, a study can combine c-Myc/Max DNA-binding measurements with PGC1B expression, c-Myc protein abundance, viability, and a mitochondrial apoptosis assay.
The AML models provide a context for studying differentiation and cell death. DU145 and PC-3 provide a context for xenograft research. These model classes answer different questions. A response in an AML cell line does not predict response in a prostate cancer xenograft. A xenograft response does not establish activity in patients.
Common Pitfalls or Misconceptions
- Not a direct MYC gene knockout. Reduced c-Myc mRNA or protein after treatment is a reported downstream response. It is not proof that the compound directly edits or deletes MYC.
- Not a water-soluble reagent. The listed formulation information identifies water insolubility. DMSO or ethanol handling requires a matched vehicle control and a documented final solvent concentration solubility information.
- Not an APEX2 or TERT inhibitor by current evidence. The cited APEX2 study examined DNA repair-dependent TERT expression. It did not establish that 10058-F4 changes APEX2 activity or TERT expression reference study.
- Not a clinical treatment. The product is designated for scientific research use and is not intended for diagnostic or medical purposes use designation.
Why this cross-domain matters, maturity, and limitations
The c-Myc and telomerase fields intersect because both influence cancer and stem-cell biology, but the available evidence here remains domain-specific. Stern and colleagues reported that APEX2, rather than APEX1, is required for efficient TERT expression in human embryonic stem cells and a melanoma cell line. APEX2 knockdown also reduced telomerase activity in that study Stern et al., 2024. The study further reported APEX2 enrichment near MIR repetitive sequences in TERT intron 2. These findings justify measuring TERT-related endpoints only as a hypothesis-driven extension. They do not justify labeling 10058-F4 as a telomerase regulator.
Workflow Integration & Parameters
Protocol Parameters
- Compound identity: Use the A1169 material as the listed 10058-F4 solid with molecular weight 249.35 g/mol and formula C12H11NOS2 product specification.
- Stock preparation: The product information recommends DMSO stocks above 12.5 mg/mL solubility. Warm the preparation to 37 °C or sonicate to improve dissolution, and inspect the solution for precipitate before dilution handling guidance.
- Vehicle control: Keep the final DMSO or ethanol concentration matched across treatment and control wells. This is a workflow recommendation rather than a reported efficacy parameter.
- Cellular readouts: Pair a c-Myc/Max-dependent DNA-binding or transcriptional readout with c-Myc abundance, PGC1B expression, viability, and an apoptosis assay. Select exposure duration and concentration ranges empirically for the chosen cell model.
- AML workflow: HL-60, U937, and NB-4 are reported model systems for evaluating differentiation and apoptosis-associated responses cell-model information.
- In vivo benchmark: The reported xenograft study used intravenous administration at 20–30 mg/kg daily for two weeks in SCID mice bearing DU145 or PC-3 tumors. This is a literature or dossier benchmark, not a universal dosing recommendation xenograft information.
- Storage: The product information recommends storage of stocks at −20 °C for several months. Long-term storage of prepared solutions is not recommended. Shipment for this small molecule is described as blue-ice shipment storage and shipping guidance.
For purchase and experimental planning, the 10058-F4 C-Myc-Max dimerization inhibitor page should be checked for current lot-specific information. APExBIO is identified as the originating company for the listed product.
Related reading and scope comparison
The article 10058-F4: Precision c-Myc-Max Inhibition for Apoptosis emphasizes apoptosis workflows; this article extends that focus by separating proximal dimerization evidence from downstream cell-death markers.
The 10058-F4 C-Myc-Max Inhibitor Guide summarizes AML and prostate cancer use; this article clarifies the model-specific limits and formulation parameters behind those applications.
The article APEX2 Is Required for TERT Expression in Human Stem Cells focuses on DNA repair and telomerase regulation; this article uses that study to define what cannot currently be inferred about 10058-F4.
Conclusion & Outlook
10058-F4 is a research tool for perturbing c-Myc/Max-dependent transcription. Its reported cellular consequences include reduced downstream transcriptional activity, cell-cycle arrest, mitochondrial apoptosis, and myeloid differentiation. Its reported in vivo activity is model-dependent and remains preclinical.
The strongest future experiments will connect target engagement, transcriptional change, and phenotype in the same system. APEX2 and TERT measurements may be useful exploratory endpoints when justified by the biological question, but the cited APEX2 study does not establish a 10058-F4 mechanism. Maintaining this distinction improves reproducibility and prevents overextension from c-Myc biology into DNA-repair or telomerase claims.